Sunday, June 04, 2006

For advanced breast cancer, Tykerb may be an alternative to Herceptin

A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive breast cancer whose disease had progressed following treatment with Trastuzumab ( Herceptin ) and other cancer therapies.In April 2006, GlaxoSmithKline ( GSK ) stopped enrollment of the study based on the unanimous recommendation of an Independent Data Monitoring Committee ( IDMC ) because it had met its primary endpoint of time to disease progression, and exceeded the predetermined stopping criteria outlined in the committee charter.Tykerb , a small molecule that is administered orally, inhibits the tyrosine kinase components of ErbB1 and ErbB2 receptors.Stimulation of ErbB1 and ErbB2 is associated with cell proliferation and with multiple processes involved in tumor progression, invasion, and metastases. Overexpression of these receptors has been reported in a variety of human tumors and is associated with poor prognosis and reduced overall survival. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */